肠促胰岛素对葡萄糖代谢的调节作用：对2型糖尿病治疗的启示
Regulation of glucose metabolism by incretins: implications for treatment of type 2 diabetes.
作者信息
Saito Rie, Harada Norio
机构信息
Department of Endocrinology and Metabolism, School of Medical Sciences, University of Fukui, 23-3 Matsuoka Shimoaizuki, Eiheiji-cho Yoshida-gun, Fukui, 910-1193 Japan.
出版信息
Diabetol Int. 2024 Dec 6;16(3):442-446. doi: 10.1007/s13340-024-00781-y. eCollection 2025 Jul.
Gastrointestinal hormones that potentiate insulin secretion from pancreatic β-cells are called incretins. Glucose-dependent insulinotropic polypeptide/gastric inhibitory polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) are the major incretins. Incretin-mediated stimulation of insulin secretion (incretin effect) plays an important role in lowering postprandial blood-glucose levels. Incretin effect is reduced under diabetic condition. Several mechanisms have been reported for the reduction of incretin effect. Incretin-related drugs are used worldwide for the treatment of type 2 diabetes. In addition, several new incretin-related drugs have been developed and are expected to be available in clinical practice.
增强胰腺β细胞胰岛素分泌的胃肠激素被称为肠促胰岛素。葡萄糖依赖性促胰岛素多肽/胃抑制多肽（GIP）和胰高血糖素样肽-1（GLP-1）是主要的肠促胰岛素。肠促胰岛素介导的胰岛素分泌刺激（肠促胰岛素效应）在降低餐后血糖水平中起重要作用。在糖尿病状态下，肠促胰岛素效应降低。已有多种机制被报道与肠促胰岛素效应降低有关。肠促胰岛素相关药物在全球范围内用于治疗2型糖尿病。此外，几种新型肠促胰岛素相关药物已被研发出来，并有望应用于临床实践。
Zotero 插件